[en] Background: There are few available therapeutic options to promote recovery among patients with chronic disorders of consciousness (DOC). Among pharmacological treatments, apomorphine, a dopamine agonist, has exhibited promising behavioral effects and safety of use in small-sample pilot studies. The true efficacy of the drug and its neural mechanism are still unclear. Apomorphine may act through a modulation of the anterior forebrain mesocircuit, but neuroimaging and neurophysiological investigations to test this hypothesis are scarce. This clinical trial aims to (1) assess the treatment effect of subcutaneous apomorphine infusions in patients with DOC, (2) better identify the phenotype of responders to treatment, (3) evaluate tolerance and side effects in this population, and (4) examine the neural networks underlying its modulating action on consciousness.
Methods/Design: This study is a prospective double-blind randomized parallel placebo-controlled trial. Forty-eight patients diagnosed with DOC will be randomized to receive a 30-day regimen of either apomorphine hydrochloride or placebo subcutaneous infusions. Patients will be monitored at baseline 30 days before initiation of therapy, during treatment and for 30 days after treatment washout, using standardized behavioral scales (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised), neurophysiological measures (electroencephalography, body temperature, actigraphy) and brain imaging (magnetic resonance imaging, positron emission tomography). Behavioral follow-up will be performed up to 2 years using structured phone interviews. Analyses will look for changes in behavioral status, circadian rhythmicity, brain metabolism, and functional connectivity at the individual level (comparing before and after treatment) and at the group level (comparing apomorphine and placebo arms, and comparing responder and non-responder groups).
Discussion: This study investigates the use of apomorphine for the recovery of consciousness in the first randomized placebo-controlled double-blind trial using multimodal assessments. The results will contribute to define the role of dopamine agonists for the treatment of these challenging conditions and identify the neural correlates to their action. Results will bring objective evidence to further assess the modulation of the anterior forebrain mesocircuit by pharmacological agents, which may open new therapeutic perspectives.
Clinical Trial Registration: EudraCT n°2018-003144-23; Clinicaltrials.gov n°NCT03623828 (https://clinicaltrials.gov/ct2/show/NCT03623828).
Research Center/Unit :
GIGA Consciousness
Disciplines :
Neurology
Author, co-author :
Sanz, Leandro ; Université de Liège - ULiège > Consciousness-Coma Science Group
Lejeune, Nicolas ; Université de Liège - ULiège > Form. doct. sc. méd. (paysage)
Laureys S, Celesia GG, Cohadon F, Lavrijsen J, León-Carrión J, Sannita WG, et al. Unresponsive wakefulness syndrome: a new name for the vegetative state or apallic syndrome. BMC Med. (2010) 8:68. 10.1186/1741-7015-8-68
Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI. The minimally conscious state. Neurology. (2002) 58:349–53. 10.1212/WNL.58.3.34911839831
Thibaut A, Bruno M-A, Ledoux D, Demertzi A, Laureys S. tDCS in patients with disorders of consciousness Sham-controlled randomized double-blind study. Neurology. (2014) 82:1112–8. 10.1212/WNL.000000000000026024574549
Thibaut A, Wannez S, Donneau AF, Chatelle C, Gosseries O, Bruno M-A, et al. Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state. Brain Inj. (2017) 31:466–74. 10.1080/02699052.2016.127477628281845
Martens G, Lejeune N, O'Brien AT, Fregni F, Martial C, Wannez S, et al. Randomized controlled trial of home-based 4-week tDCS in chronic minimally conscious state. Brain Stimul. (2018) 11:982–90. 10.1016/j.brs.2018.04.02129759943
Estraneo A, Pascarella A, Moretta P, Masotta O, Fiorenza S, Chirico G, et al. Repeated transcranial direct current stimulation in prolonged disorders of consciousness: a double-blind cross-over study. J Neurol Sci. (2017) 375:464–70. 10.1016/j.jns.2017.02.03628320187
Chudy D, Deletis V, Almahariq F, Marčinković P, Škrlin J, ParadŽik V. Deep brain stimulation for the early treatment of the minimally conscious state and vegetative state: experience in 14 patients. J Neurosurg. (2018) 128:1189–98. 10.3171/2016.10.JNS16107128621620
Magrassi L, Maggioni G, Pistarini C, Di Perri C, Bastianello S, Zippo AG, et al. Results of a prospective study (CATS) on the effects of thalamic stimulation in minimally conscious and vegetative state patients. J Neurosurg. (2016) 125:972–81. 10.3171/2015.7.JNS1570026745476
Schiff ND, Giacino JT, Kalmar K, Victor JD, Baker K, Gerber M, et al. Behavioural improvements with thalamic stimulation after severe traumatic brain injury. Nature. (2007) 448:600–3. 10.1038/nature0604117671503
Thonnard M, Gosseries O, Demertzi A, Lugo Z, Vanhaudenhuyse A, Bruno M-A, et al. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study. Funct Neurol. (2014) 28:259–64. 10.11138/FNeur/2013.28.4.25924598393
Whyte J, Rajan R, Rosenbaum A, Katz D, Kalmar K, Seel R, et al. Zolpidem and restoration of consciousness. Am J Phys Med Rehabil. (2014) 93:101–13. 10.1097/PHM.000000000000006924434886
Nicola SM, Surmeier DJ, Malenka RC, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci. (2000) 23:185–215. 10.1146/annurev.neuro.23.1.18510845063
Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. (2001) 21:1787–94. 10.1523/JNEUROSCI.21-05-01787.200111222668
Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 1. J Head Trauma Rehabil. (2000) 15:1179–82. 10.1097/00001199-200010000-0001410970937
Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 2. J Head Trauma Rehabil. (2001) 16:112–6. 10.1097/00001199-200102000-0001411277855
Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. (2014) 20:4167–84. 10.2174/1381612811319666065424025057
Matsuda W, Komatsu Y, Yanaka K, Matsumura A. Levodopa treatment for patients in persistent vegetative or minimally conscious states. Neuropsychol Rehabil. (2005) 15:414–27. 10.1080/09602010443000588
Ugoya SO, Akinyemi RO. The place of l-dopa/carbidopa in persistent vegetative state. Clin Neuropharmacol. (2010) 33:279–84. 10.1097/WNF.0b013e318201107021060281
Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine. Arch Phys Med Rehabil. (2001) 82:311–5. 10.1053/apmr.2001.2083111245751
Whyte J, Vaccaro M, Grieb-Neff P, Hart T, Polansky M, Coslett HB. The effects of bromocriptine on attention deficits after traumatic brain injury. Am J Phys Med Rehabil. (2008) 87:85–99. 10.1097/PHM.0b013e318161960918209510
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. (2012) 366:819–26. 10.1056/NEJMoa110260922375973
Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Practice guideline update recommendations summary: disorders of consciousness. Neurology. (2018) 91:450–60. 10.1212/WNL.000000000000592630089618
Fridman EA, Calvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj. (2009) 23:172–7. 10.1080/0269905080264966219191097
Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. (2010) 24:636–41. 10.3109/0269905100361043320235766
Anden NE, Rubenson A, Fuxe K, Hokfelt T. Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol. (1967) 19:627–9. 10.1111/j.2042-7158.1967.tb09604.x4383150
Ribarič S. The pharmacological properties and therapeutic use of apomorphine. Molecules. (2012) 17:5289–309. 10.3390/molecules1705528922565480
Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J Neural Transm Suppl. (1995) 45:137–41. 8748619
Bhidayasiri R, Garcia PJ, Henriksen T. Parkinsonism and related disorders practical management of adverse events related to apomorphine therapy. Park Relat Disord. (2016) 33:S42–8. 10.1016/j.parkreldis.2016.11.017
Boyle A, Ondo W. Role of apomorphine in the treatment of Parkinson's disease. CNS Drugs. (2015) 29:83–9. 10.1007/s40263-014-0221-z25676564
Schiff ND. Recovery of consciousness after brain injury: a mesocircuit hypothesis. Trends Neurosci. (2010) 33:1–9. 10.1016/j.tins.2009.11.00219954851
Fridman EA, Beattie BJ, Broft A, Laureys S, Schiff ND. Regional cerebral metabolic patterns demonstrate the role of anterior forebrain mesocircuit dysfunction in the severely injured brain. Proc Natl Acad Sci USA. (2014) 111:6473–8. 10.1073/pnas.132096911124733913
Fischer DB, Boes AD, Demertzi A, Evrard HC, Laureys S, Edlow BL, et al. A human brain network derived from coma-causing brainstem lesions. Neurology. (2016) 87:2427–34. 10.1212/WNL.000000000000340427815400
Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, et al. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med. (2000) 27:1410–4. 10.1007/s00259000030811007526
Wagner AK, Scanlon JM, Becker CR, Ritter AC, Niyonkuru C, Dixon CE, et al. The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI. J Cereb Blood Flow Metab. (2014) 34:1328–39. 10.1038/jcbfm.2014.8724849661
Giacino JT, Fins JJ, Laureys S, Schiff ND. Disorders of consciousness after acquired brain injury: the state of the science. Nat Rev Neurol. (2014) 10:99–114. 10.1038/nrneurol.2013.27924468878
Laureys S, Faymonville M, Luxen A, Lamy M, Franck G, Maquet P. Restoration of thalamocortical connectivity after recovery from persistent vegetative state. Lancet. (2000) 355:1790–1. 10.1016/S0140-6736(00)02271-610832834
Giacino JT, Kalmar K, Whyte J. The JFK coma recovery scale-revised: measurement characteristics and diagnostic utility. Arch Phys Med Rehabil. (2004) 85:2020–9. 10.1016/j.apmr.2004.02.03315605342
Chatelle C, Majerus S, Whyte J, Laureys S, Schnakers C. A sensitive scale to assess nociceptive pain in patients with disorders of consciousness. J Neurol Neurosurg Psychiatry. (2012) 83:1233–7. 10.1136/jnnp-2012-30298722906615
Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. (2014) 13:131–8. 10.1517/14740338.2014.85119324147629
Food and Drug Administration. FDA Approved Labeling Text for NDA 021264 (2010).
Levin HS, Boake C, Song J, Cauley SMC, Contant C, Diaz-marchan P, et al. Validity and sensitivity to change of the extended glasgow outcome scale in mild to moderate traumatic brain. Injury. (2001) 18:575–84. 10.1089/08977150175029181911437080
Seel RT, Sherer M, Whyte J, Katz DI, Giacino JT, Rosenbaum AM, et al. Assessment scales for disorders of consciousness: evidence-based recommendations for clinical practice and research. Arch Phys Med Rehabil. (2010) 91:1795–813. 10.1016/j.apmr.2010.07.21821112421
Sattin D, Minati L, Rossi D, Covelli V, Giovannetti AM, Rosazza C, et al. The coma recovery scale modified score. Int J Rehabil Res. (2015) 38:350–6. 10.1097/MRR.000000000000013526465775
Schnakers C, Majerus S, Giacino J, Vanhaudenhuyse A, Bruno MA, Boly M, et al. A French validation study of the Coma Recovery Scale-Revised (CRS-R). Brain Inj. (2008) 22:786–92. 10.1080/0269905080240355718787989
Blume C, Lechinger J, Santhi N, Giudice R, del Gnjezda M-T, Pichler G, et al. Significance of circadian rhythms in severely brain-injured patients. Neurology. (2017) 88:1933–41. 10.1212/WNL.000000000000394228424270
Cruse D, Thibaut A, Demertzi A, Nantes JC, Bruno M-A, Gosseries O, et al. Actigraphy assessments of circadian sleep-wake cycles in the Vegetative and Minimally Conscious States. BMC Med. (2013) 11:18. 10.1186/1741-7015-11-1823347467
Matsumoto M, Sugama J, Okuwa M, Dai M, Matsuo J, Sanada H. Non-invasive monitoring of core body temperature rhythms over 72h in 10 bedridden elderly patients with disorders of consciousness in a Japanese hospital: a pilot study. Arch Gerontol Geriatr. (2013) 57:428–32. 10.1016/j.archger.2013.05.009
Murphy M, Bruno M-A, Riedner BA, Boveroux P, Noirhomme Q, Landsness EC, et al. Propofol anesthesia and sleep: a high-density EEG study. Sleep. (2011) 34:283–91. 10.1093/sleep/34.3.28321358845
Kane NM, Curry SH, Butler SR, Cummins BH. Electrophysiological indicator of awakening from coma. Lancet. (1993) 341:688. 10.1016/0140-6736(93)90453-N8095587
Wijnen VJM, van Boxtel GJM, Eilander HJ, de Gelder B. Mismatch negativity predicts recovery from the vegetative state. Clin Neurophysiol. (2007) 118:597–605. 10.1016/j.clinph.2006.11.02017239656
Bekinschtein TA, Dehaene S, Rohaut B, Tadel F, Cohen L, Naccache L. Neural signature of the conscious processing of auditory regularities. Proc Natl Acad Sci USA. (2009) 106:1672–7. 10.1073/pnas.080966710619164526
Engemann DA, Raimondo F, King J-R, Rohaut B, Louppe G, Faugeras F, et al. Robust EEG-based cross-site and cross-protocol classification of states of consciousness. Brain. (2018) 141:3179–92. 10.1093/brain/awy25130285102
Sitt JD, King J-R, El Karoui I, Rohaut B, Faugeras F, Gramfort A, et al. Large scale screening of neural signatures of consciousness in patients in a vegetative or minimally conscious state. Brain. (2014) 137:2258–70. 10.1093/brain/awu141
Chennu S, Annen J, Wannez S, Thibaut A, Chatelle C, Cassol H, et al. Brain networks predict metabolism, diagnosis and prognosis at the bedside in disorders of consciousness. Brain. (2017) 140:2120–32. 10.1093/brain/awx16328666351
Stender J, Kupers R, Rodell A, Thibaut A, Chatelle C, Bruno M-A, et al. Quantitative rates of brain glucose metabolism distinguish minimally conscious from vegetative state patients. J Cereb Blood Flow Metab. (2015) 35:58–65. 10.1038/jcbfm.2014.16925294128
Stender J, Mortensen KN, Thibaut A, Darkner S, Laureys S, Gjedde A, et al. The minimal energetic requirement of sustained awareness after brain injury. Curr Biol. (2016) 26:1494–9. 10.1016/j.cub.2016.04.02427238279
Annen J, Frasso G, Crone JS, Heine L, Di Perri C, Martial C, et al. Regional brain volumetry and brain function in severely brain-injured patients. Ann Neurol. (2018) 83:842–53. 10.1002/ana.2521429572926
Demertzi A, Antonopoulos G, Heine L, Voss HU, Crone JS, de Los Angeles C, et al. Intrinsic functional connectivity differentiates minimally conscious from unresponsive patients. Brain. (2015) 138:2619–31. 10.1093/brain/awv16926117367
Kirsch M, Guldenmund P, Ali Bahri M, Demertzi A, Baquero K, Heine L, et al. Sedation of patients with disorders of consciousness during neuroimaging: effects on resting state functional brain connectivity. Anesth Analg. (2017) 124:588–98. 10.1213/ANE.000000000000172127941576
Whyte J, Gosseries O, Chervoneva I, DiPasquale MC, Giacino J, Kalmar K, et al. Predictors of short-term outcome in brain-injured patients with disorders of consciousness. Prog Brain Res. (2009) 177:63–72. 10.1016/S0079-6123(09)17706-319818895
Stender J, Gosseries O, Bruno M-A, Charland-Verville V, Vanhaudenhuyse A, Demertzi A, et al. Diagnostic precision of PET imaging and functional MRI in disorders of consciousness: a clinical validation study. Lancet. (2014) 384:514–22. 10.1016/S0140-6736(14)60042-824746174
Annen J, Heine L, Ziegler E, Frasso G, Bahri M, Di Perri C, et al. Function–structure connectivity in patients with severe brain injury as measured by MRI-DWI and FDG-PET. Hum Brain Mapp. (2016) 37:3707–20. 10.1002/hbm.2326927273334
Di Perri C, Bahri MA, Amico E, Thibaut A, Heine L, Antonopoulos G, et al. Neural correlates of consciousness in patients who have emerged from a minimally conscious state: a cross-sectional multimodal imaging study. Lancet Neurol. (2016) 15:830–42. 10.1016/S1474-4422(16)00111-3
Fox M, Zhang D. The global signal and observed anticorrelated resting state brain networks. J Neurophysiol. (2009) 101:3270–83. 10.1152/jn.90777.200819339462
Rutgeerts P, Robert L, Helmut M, Cornelis L, Gunnar O, Derek J, et al. Medical aspects of the persistent vegetative state. N Engl J Med. (1994) 330:1499–508. 10.1056/NEJM199405263302107
van Erp WS, Lavrijsen JCM, Vos PE, Bor H, Laureys S, Koopmans RTCM. The vegetative state: prevalence, misdiagnosis, and treatment limitations. J Am Med Dir Assoc. (2015) 16:85.e9-14. 10.1016/j.jamda.2014.10.014
Schnakers C, Vanhaudenhuyse A, Giacino J, Ventura M, Boly M, Majerus S, et al. Diagnostic accuracy of the vegetative and minimally conscious state: clinical consensus versus standardized neurobehavioral assessment. BMC Neurology. (2009) 9:35. 10.1186/1471-2377-9-3519622138
Schnakers C, Monti MM. Disorders of consciousness after severe brain injury. Curr Opin Neurol. (2017) 30:573–9. 10.1097/WCO.000000000000049528901969
Ciurleo R, Bramanti P. Pharmacotherapy for disorders of consciousness: are ‘ awakening ’ drugs really a possibility? Drugs. (2013)73:1849–62. 10.1007/s40265-013-0138-824170667
